A review: Integrin αvβ3-targeted molecular imaging and therapy in angiogenesis

Esther H. Lim, Narasimhan Danthi, Mark Bednarski, King C.P. Li

Research output: Contribution to journalReview articlepeer-review

Abstract

Integrin αvβ3 provides numerous possibilities for diagnostic imaging probes and therapeutic potentials for angiogenesis research. There has been significant advancement since it was first discovered as an endothelial marker responsible for angiogenesis. There are hundreds of patents and publications on integrin αvβ3 targeting antibodies, peptides, and peptidomimetics. Additionally, ligand array of integrin antagonists on nanoparticles has proven a viable strategy to target vascular surface receptors on endothelial cells. The results of ongoing clinical trials of the two most advanced αvβ3-integrin antagonists, Vitaxin and Cilengitide, are enthusiastically awaited for further drug discovery research efforts of other antiangiogenic drugs. More recent development of small peptidomimetic molecules modified for obtaining more selective targeting has provided ligands with higher binding affinity. Preclinical studies with these synthetic ligands are promising, and there is continued effort to modify these ligands to improve pharmacokinetics and imaging characteristics for the development of imaging probes and therapeutic agents. Synergistic effects seen with polyvalent materials are being pursued by making multivalent molecules. Considerable advances in nanoparticle research has enabled us to further optimize controlled delivery as well as site-specific delivery. This multivalent nanoparticle technology combined with high-affinity, target-specific ligands would further help achieve high selectivity, increased receptor affinity, and improved tracer properties through multilevel synergy. Moreover, the use of this targeting system as vectors for drug delivery will significantly increase selectivity to the target without undesirable systemic toxicity. As translation of these integrin-targeting approaches toward clinical settings progresses, potential uses of these imaging and therapeutic agents in the clinic will soon become a reality.

Original languageEnglish (US)
Pages (from-to)110-114
Number of pages5
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume1
Issue number2
DOIs
StatePublished - Jun 2005
Externally publishedYes

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'A review: Integrin α<sub>v</sub>β<sub>3</sub>-targeted molecular imaging and therapy in angiogenesis'. Together they form a unique fingerprint.

Cite this